The UK government has begun the roll-out of MSD’s Lagevrio (molnupiravir), the first oral antiviral treatment for COVID-19, but is taking a cautious approach to its use amid signs it may not be the ‘game changer’ that was initially hoped.
The government has decided to recruit 10,000 at-risk individuals to a trial of Lagevrio to gather further data following uncertainties...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)